InMode Anticipates Strong Q1 2026 Financial Results and Conference Call Announcement
On April 13, 2026, InMode Ltd., a prominent global leader in medical technology, shared insights regarding its anticipated financial performance for the first quarter of 2026. The company, which is prominently listed on Nasdaq under the symbol INMD, is preparing to release its official financial results before the Nasdaq market opens on May 6, 2026. Adjustments and further developments may occur before finalization; however, preliminary results indicate that InMode projects its revenues for Q1 2026 to land between $81.5 million and $81.7 million.
As part of the financial update, management has also provided guidance for the gross margin, estimating a non-GAAP gross margin between 75% and 76%. This metric provides insights into the company’s profitability, excluding share-based compensation, which is significant for investors looking to gauge InMode's financial health and operational efficiency.
Looking beyond the immediate quarter, InMode projects a robust revenue forecast for the entire fiscal year of 2026, anticipating total revenues to fall within the range of $365 million to $375 million. This optimistic outlook speaks to InMode’s consistent growth trajectory and its strategic positioning in the medical technology sector, particularly in innovative applications leveraging radio frequency technologies across multiple medical fields.
To further discuss these results and their implications, InMode will hold a conference call on May 6, 2026, at 8:30 a.m. Eastern Time. Presenters will include notable company leaders such as Moshe Mizrahy (CEO), Yair Malca (CFO), and Dr. Michael Kreindel (CTO), who will address investor concerns and outline future strategies. Participants are encouraged to pre-register for the call through a dedicated link provided by the company, which allows for immediate access on the day of the event.
For those who prefer not to pre-register, alternative dialing options will be available. U.S. callers can use the toll-free number at 1-833-316-0562, while international participants may access a different line at 1-412-317-5736. To complement the audio experience, a live webcast of the conference call will also be accessible through the InMode website, ensuring that broader audiences can engage with the company’s updates in real-time.
Replays of the conference will be made available following the event, allowing attendees and stakeholders who were unable to join live to catch up on the discussions. The replay will be accessible via designated calling numbers and will be hosted on InMode's official website, ensuring accessibility for all interested parties.
InMode stands out as a frontrunner in developing and marketing advanced medical technologies, focusing on innovative solutions applicable to surgical procedures, as well as enhancing existing treatments across various medical disciplines, including plastic surgery, gynecology, dermatology, and more. As they prepare to unveil Q1 results, stakeholders will be particularly keen on assessing how InMode’s strategic initiatives translate into tangible performance metrics, further cementing its role in the competitive landscape of medical technology.
For those looking to stay informed, we recommend keeping an eye on InMode's continuous updates leading up to their financial release and participating in the upcoming conference call to gain firsthand insights on their operational performance and strategic direction moving forward. This combination of transparency and engagement with investors reflects InMode’s commitment to not only advance medical technology but also to maintain a robust dialogue with stakeholders as they navigate the complexities of the market.
As part of the financial update, management has also provided guidance for the gross margin, estimating a non-GAAP gross margin between 75% and 76%. This metric provides insights into the company’s profitability, excluding share-based compensation, which is significant for investors looking to gauge InMode's financial health and operational efficiency.
Looking beyond the immediate quarter, InMode projects a robust revenue forecast for the entire fiscal year of 2026, anticipating total revenues to fall within the range of $365 million to $375 million. This optimistic outlook speaks to InMode’s consistent growth trajectory and its strategic positioning in the medical technology sector, particularly in innovative applications leveraging radio frequency technologies across multiple medical fields.
To further discuss these results and their implications, InMode will hold a conference call on May 6, 2026, at 8:30 a.m. Eastern Time. Presenters will include notable company leaders such as Moshe Mizrahy (CEO), Yair Malca (CFO), and Dr. Michael Kreindel (CTO), who will address investor concerns and outline future strategies. Participants are encouraged to pre-register for the call through a dedicated link provided by the company, which allows for immediate access on the day of the event.
For those who prefer not to pre-register, alternative dialing options will be available. U.S. callers can use the toll-free number at 1-833-316-0562, while international participants may access a different line at 1-412-317-5736. To complement the audio experience, a live webcast of the conference call will also be accessible through the InMode website, ensuring that broader audiences can engage with the company’s updates in real-time.
Replays of the conference will be made available following the event, allowing attendees and stakeholders who were unable to join live to catch up on the discussions. The replay will be accessible via designated calling numbers and will be hosted on InMode's official website, ensuring accessibility for all interested parties.
InMode stands out as a frontrunner in developing and marketing advanced medical technologies, focusing on innovative solutions applicable to surgical procedures, as well as enhancing existing treatments across various medical disciplines, including plastic surgery, gynecology, dermatology, and more. As they prepare to unveil Q1 results, stakeholders will be particularly keen on assessing how InMode’s strategic initiatives translate into tangible performance metrics, further cementing its role in the competitive landscape of medical technology.
For those looking to stay informed, we recommend keeping an eye on InMode's continuous updates leading up to their financial release and participating in the upcoming conference call to gain firsthand insights on their operational performance and strategic direction moving forward. This combination of transparency and engagement with investors reflects InMode’s commitment to not only advance medical technology but also to maintain a robust dialogue with stakeholders as they navigate the complexities of the market.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.